Icon

SINGULAIR (nda020829)- (EQ 10MG BASE)

MONTELUKAST SODIUM ORGANON
EQ 10MG BASE
Yes No
2012-Aug-03 Expired
None None
None No
SINGULAIR is a leukotriene receptor antagonist indicated for:  Prophylaxis and chronic treatment of asthma in patients 12 months of age and older.  Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older.  Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies.
17 0 14
Total Other Developers 7
Drugs with Suitability No
EQ 10MG BASE ** ** Up - 9
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ****** *** ****** ******* ******* *********** **** **. *-*/* *** *-*, *** ********** **** ***** *****, ******* *****, **** ******, *********** ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *** *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *** *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ** ****** **** *** **. *****'* ************ ******* *********** ****** **. **, ** ****, ** **** & ** ****, ********** ******* *** ******, *******-********** ********,, *******-**********, ********* ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ****** **** *** * ****** *************** *** *********** *** ******** **, *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ******* ******** *** ********* ************** ******* ******* *********** ***** **. ***/*** *** ****/***/*, **** **, ****** ****, (** *) ******* *****, *********** *****, *********, ** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** **** **. ** ** **, ******* ********** ******, *******, ******, *** ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* *** ******** ******** ******** ************** **.,*** *********** *** ***'** **** ******** ********, ********, ******** ******, ***** (***) ***
****** ****** ******* *************** ******* ******* *********** ****** **. ***/* & ***/**, ******* *******, ********** ******, **********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.